ALTAltimmune, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−37% vs 200-day) and a crowded short (+24% of shares).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 20). Price is −37% vs its 200-day average.
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ALT is trading
Altimmune, Inc. is −46% over the past year while the S&P 500 is +16%: 62 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- −37%
vs 200-day average · a clear downtrend
- RSI (14)
- 20
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 66%
Below its 52-week high
Details›
- Last close2026-10-23
- $2.11
- 1 monthS&P 500 −0.94%
- −31%
- 1 yearS&P 500 +16%
- −46%
- 5 yearsS&P 500 +86%
- −82%
- vs 50-day average$2.92
- −28%
- 52-week high
- $6.18
- 52-week low
- $2.11
- Annualised volatility
- 82%
| Year | Return |
|---|---|
| 2026 (year to date) | −42% |
| 2025 | −50% |
| 2024 | −36% |
| 2023 | −32% |
| 2022 | +80% |
| 2021 | −19% |
| 2020 | +497% |
| 2019 | −8.3% |
| 2018 | −97% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 9 | 3 of 9 | +7.3% |
| Feb | 9 | 4 of 9 | +9.8% |
| Mar | 9 | 1 of 9 | −22% |
| Apr | 9 | 3 of 9 | −10% |
| May | 9 | 5 of 9 | +21% |
| Jun | 10 | 2 of 10 | +1.7% |
| Jul | 10 | 3 of 10 | +7.6% |
| Aug | 10 | 5 of 10 | +9.1% |
| Sep | 10 | 1 of 10 | −17% |
| Oct | 10 | 3 of 10 | −4.8% |
| Nov | 9 | 4 of 9 | +4.0% |
| Dec | 9 | 4 of 9 | +25% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.